Elan chairman Robert Ingram at the company’s EGM in Dublin today. Photograph: Aidan Crawley

Elan shareholders decisively rejected a major investment programme proposed by the company at a special meeting in Dublin today.However, investors nar(...)

Royalty Pharma’s $6.7 billion offer for Irish pharmacuetical firm Elan has now lapsed

Pharmaceutical firm Elan has initiated a formal sale process following the approval this morning of its share buyback programme. In accordance with(...)

Royalty Pharma’s hostile bid for Irish pharmaceutical firm Elan continues as its chairman asserts that “no other bona fide buyer” is interested in Elan. (Photo:John Cogill/Bloomberg News)

Ahead of Elan’s egm later today, at which shareholders will vote on a series of acquisitions undertaken by the Irish pharmaceutical firm, the chairman(...)

Elan chief executive Kelly Martin: the firm faces a critical moment in its volatile history with tomorrow’s EGM.

Irish biotech group Elan has been through many critical moments in its volatile history. Tomorrow, shareholders gather for an extraordinary general me(...)

Elan shareholders vote on four proposed investments by the company at an EGM on Monday.Photographer: Dara Mac Dónaill

A High Court judge has granted an injunction effectively keeping alive Royalty Pharma’s $6.7 billion offer for Elan pending the outcome of a full lega(...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

On Monday, shareholders gather in Dublin, potentially to decide the fate of the company

Shareholders at Elan have seen a lot through the years. But even they must be nonplussed by the frantic claim and counterclaim being put about by the (...)

Pharmaceutical firm Elan has urged shareholders to reject “grossly inadequate” offer from Royalty Pharma

In the latest development in Royalty Pharma’s attempt to take over Elan, the Irish pharmaceutical firm has urged shareholders to “protect the value of(...)

Drug company Elan last night dropped a legal action in New York against Royalty Pharmaceuticals, the company locked in a €6.7 billion takeover battle (...)

Elan and Royalty Pharma have dismissed each others’ valuations of future sales of Tysabri, Elan’s multiple sclerosis drug sold to its partner Biogen Idec this year in a deal that freed cash and set Elan on an acquisition trail for new investments.

The bitter battle for Elan intensified yesterday after private equity group Royalty Pharma raised its all-cash offer for the Irish-based speciality dr(...)